Labiotech.eu

News and Trends 9 Mar 2015

MorphoSys and Emergent BioSolutions Initiate Phase I

MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). A few months ago, we talked about the beginning of the collaboration between MorphoSys and Emergent BioSolutions. Now, the fruit of their combined work, an […]

March 9, 2015 - 3 minutesmins - By Lourdes Riquelme

LaBiotech Zurich Life Science Day2 cover

News and Trends 9 Mar 2015

An Inside Look: Zurich Life Science Day 2015

Over 600 people from all stretches of the globe gathered on February 12 for the Zurich Life Science Day at the University of Zurich. My first impression walking there was that the campus (both the Irchel campus it was held at and main campus I mistakenly went to first) were beautiful. I had low expectations […]

March 9, 2015 - 7 minutesmins - By Joachim Eeckhout

News and Trends 7 Mar 2015

New insights into drought tolerance in plants

Spanish researchers found a new family of proteins that controls plant resistance to drought. The work will allow the design of crop plants with improved properties over this type of stress. Two teams of the Spanish National Research Council (CSIC in Spanish) have identified and characterized a new protein family that directly controls the drought […]

March 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Novartis achieves the First Biosimilar approval in US

The Novartis company Sandoz has become the first company with a biosimilar approved by the US Food and Drug Administration (FDA) after today’s approval of Zarxio, a treatment for neutropenia. Sandoz is the first company to receive the approval of a biosimilar in the US through the new FDA biosimilars pathway established under Biologics Price […]

March 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Petunica circadia, where Art and Biotechnology meet

A changing-color flower that goes from blue to red and viceversa? It may sound like science fiction, but it’s purely biotechnology. A simple petunia to make a statement: gene engineering is not something to be afraid of. Biotechnology has so many applications that go from nourishing the increasing world population to growing beautiful flowers to […]

March 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 6 Mar 2015

Global Bioenergies Produces its First “Second Generation” Isobutene

We already presented Global Bioenergies in our article “Is France leading the European Synthetic Biology-based Biofuel field?”, but as a reminder the company is developing a process to convert renewable resources into hydrocarbons (more specifically isobutene, a building blocks that can be converted into fuels, plastics, organic glass and elastomers) through fermentation. Global Bioenergies annouced having […]

March 6, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 5 Mar 2015

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small […]

March 5, 2015 - 5 minutesmins - By Cédric Brock

News and Trends 5 Mar 2015

Synpromics and UniQure, new Collaboration in Gene Therapy.

Synpromics has formed a collaboration with uniQure, the Dutch pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene therapies to liver. Synpromics, a leading synthetic biology company, will use its unique approach to develop synthetic promoters with upregulated, liver cell specific, activity whilst also decreasing the promoter molecular […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Mar 2015

Baxter’s Bioscience Business Acquires SuppreMol

Baxter has acquired SuppreMol for €200M before working capital and other adjustments. The acquisition includes SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases, focusing on the modulation of Fc […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

Bavarian Nordic Bristol Myers Squibb cancer

News and Trends 4 Mar 2015

Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC

Bristol-Myers Squibb signs an exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy. Bavarian Nordic will receive up to €880.4M. Bristol-Myers Squibb will have the exclusive option to license and commercialize PROSTVAC, Bavarian Nordic’s investigational Phase III prostate-specific antigen (PSA) in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant

Boehringer Ingelheim submitted idarucizumab for approval of marketing authorization to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canada. The submission is directed to patients who require rapid reversal of the anticoagulant effect of dabigatran, the active ingredient in Boehringer Ingelheim’s Pradaxa. Pradaxa, a direct thrombin inhibitor (DTI), was the first […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Mar 2015

Alkermes presents its new treatment of Alzheimer’s agitation

Alkermes reveals a new drug candidate, ALKS 7119, for treatment of Alzheimer’s agitation, depression and other central nervous system (CNS) diseases. Alkermes has successfully completed preclinical development and expects to initiate the first clinical study of its newest candidate, ALKS 7119, in the third quarter of 2015. ALKS 7119 has a multivalent mechanism of action […]

March 4, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

MorphoSys and Emergent BioSolutions Initiate Phase I

An Inside Look: Zurich Life Science Day 2015

New insights into drought tolerance in plants

Novartis achieves the First Biosimilar approval in US

Petunica circadia, where Art and Biotechnology meet

Global Bioenergies Produces its First “Second Generation” Isobutene

Novartis announces completion of transactions with GSK

Synpromics and UniQure, new Collaboration in Gene Therapy.

Baxter’s Bioscience Business Acquires SuppreMol

Bristol-Myers Squibb signs an agreement for Bavarian Nordic’s PROSTVAC

Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant

Alkermes presents its new treatment of Alzheimer’s agitation

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!